OCGN is trading at 6% up now at $1.56 after Canaccord kept its Buy rating while trimming its price target from $12 to $11.[1] Investor sentiment also stayed upbeat because the firm cited strong clinical data and two ongoing pivotal trials as key pipeline drivers.[1] The move is being reinforced by elevated trading interest, with recent volume notably above normal levels.[3][7]